VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $171,000 | -40.8% | 11,763 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $289,000 | -21.3% | 11,763 | -35.5% | 0.00% | -33.3% |
| Q2 2016 | $367,000 | -25.7% | 18,238 | 0.0% | 0.01% | -25.0% |
| Q1 2016 | $494,000 | -73.4% | 18,238 | 0.0% | 0.01% | -69.2% |
| Q4 2015 | $1,854,000 | -64.7% | 18,238 | -38.0% | 0.03% | -62.9% |
| Q3 2015 | $5,251,000 | -21.3% | 29,438 | -2.0% | 0.07% | -4.1% |
| Q2 2015 | $6,673,000 | +8.2% | 30,038 | -3.2% | 0.07% | +14.1% |
| Q1 2015 | $6,165,000 | -0.4% | 31,038 | -28.2% | 0.06% | 0.0% |
| Q4 2014 | $6,188,000 | -47.4% | 43,238 | -51.8% | 0.06% | -48.0% |
| Q3 2014 | $11,764,000 | +84.4% | 89,664 | +77.2% | 0.12% | +98.4% |
| Q2 2014 | $6,381,000 | +109.6% | 50,592 | +119.0% | 0.06% | +106.7% |
| Q1 2014 | $3,045,000 | -16.6% | 23,100 | -25.7% | 0.03% | -16.7% |
| Q4 2013 | $3,651,000 | +12.5% | 31,100 | 0.0% | 0.04% | +5.9% |
| Q3 2013 | $3,245,000 | +21.2% | 31,100 | 0.0% | 0.03% | +17.2% |
| Q2 2013 | $2,677,000 | – | 31,100 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |